CollPlant Biotechnologies Ltd. (CLGN)
Stock Price:
$6.76 USD
-0.46 (-6.37%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
43.72M |
| Revenue (ttm) |
2.55M |
| Net Income (ttm) |
-11.18M |
| Shares Out |
6.47M |
| EPS (ttm) |
-1.86 |
| PE Ratio |
n/a |
| Forward PE |
158.73 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$6.76 |
| Previous Close |
$7.22 |
| Change ($) |
-0.46 |
| Change (%) |
-6.37% |
| Day's Open |
7.20 |
| Day's Range |
6.75 - 7.40 |
| Day's Volume |
10,171 |
| 52-Week Range |
3.75 - 14.55 |
More Stats
| Market Cap |
43.72M |
| Enterprise Value |
43.46M |
| Earnings Date (est) |
Nov 27, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
6.47M |
| Float |
n/a |
| EPS (basic) |
-1.99 |
| EPS (diluted) |
-1.86 |
| FCF / Share |
-1.17 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1,287 |
| Short Ratio |
0.10 |
| Short % of Float |
n/a |
| Beta |
0.57 |
| PE Ratio |
n/a |
| Forward PE |
158.73 |
| P/FCF Ratio |
n/a |
| PS Ratio |
17.15 |
| PB Ratio |
8.21 |
| Revenue |
2.55M |
| Operating Income |
-8.11M |
| Net Income |
-11.18M |
| Free Cash Flow |
-8.15M |
| Net Cash |
265,000 |
| Net Cash / Share |
0.04 |
| Gross Margin |
17.22% |
| Operating Margin |
-317.92% |
| Profit Margin |
-438.40% |
| FCF Margin |
-319.65% |
| ROA |
-48.57% |
| ROE |
-295.81% |
| ROIC |
-93.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$14.00*
(107.10% upside)
Low
13.0
Current: $6.76
High
15.0
Target: 14.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 2.32 | 5.01 | 0.46 | 0.08 | - |
| Revenue Growth | -53.77% | 982.94% | 470.37% | - | - |
| Gross Profit | 0.44 | 3.36 | 0.42 | 0.08 | - |
| Operating Income | -7.63 | -4.25 | -5.96 | -7.66 | -5.23 |
| Net Income | -11.16 | -6.25 | -6.05 | -7.75 | -5.18 |
| Shares Outstanding | 4.99 | 4.38 | 2.66 | 0.56 | 0.47 |
| Earnings Per Share | -2.23 | -1.43 | -2.27 | -3.89 | -3.06 |
| Operating Cash Flow | -5.70 | -1.22 | -4.97 | -5.38 | -4.03 |
| Capital Expenditures | -1.46 | -0.83 | -0.13 | -0.14 | -0.39 |
| Free Cash Flow | -7.16 | -2.05 | -5.09 | -5.52 | -4.42 |
| Cash & Equivalents | 3.79 | 5.35 | 4.95 | 1.06 | - |
| Total Debt | 3.62 | 0.04 | 3.51 | - | - |
| Net Cash / Debt | 0.17 | 5.31 | 1.44 | 1.06 | - |
| Assets | 10.75 | 8.75 | 7.80 | 4.01 | - |
| Liabilities | 6.66 | 3.33 | 5.27 | 2.58 | - |
| Book Value | 4.09 | 5.42 | 2.53 | 1.43 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CollPlant Biotechnologies Ltd. |
| Country |
Israel |
| Employees |
38 |
| CEO |
Yehiel Tal |
Stock Information
| Ticker Symbol |
CLGN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CLGN |
Description
CollPlant Biotechnologies, a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.